MIRA Pharmaceuticals, Inc. Increase (Decrease) in Accounts Payable and Accrued Liabilities
MIRA Pharmaceuticals, Inc. (MIRA) reported Increase (Decrease) in Accounts Payable and Accrued Liabilities of -$88.38 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities · last filed 2026-08-12
- MIRA Pharmaceuticals, Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2026-06-30 was $6.82K, a 96.46% decline year-over-year.
- MIRA Pharmaceuticals, Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2026-03-31 was -$95.19K.
- MIRA Pharmaceuticals, Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-12-31 was $45.28K, a 48.38% increase year-over-year.
- MIRA Pharmaceuticals, Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-09-30 was -$214.53K.
- MIRA Pharmaceuticals, Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2025 was -$594.15K, a 421.53% decline from fiscal 2024.
- MIRA Pharmaceuticals, Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2024 was $184.78K.
- MIRA Pharmaceuticals, Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2023 was -$389.52K, a 356.13% decline from fiscal 2022.
- MIRA Pharmaceuticals, Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2022 was $152.08K.
| Period end | Increase (Decrease) in Accounts Payable and Accrued Liabilities 3 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 6 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 9 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $6.82K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | -$88.38K 10-Q · filed 2026-08-12 | -$43.10K derived: sum of 3 quarters · filed 2026-08-12 | -$257.63K derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | -$95.19K 10-Q · filed 2026-05-14 | -$49.92K derived: sum of 2 quarters · filed 2026-05-14 | -$264.45K derived: sum of 3 quarters · filed 2026-05-14 | -$72.17K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $45.28K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | -$169.25K derived: sum of 2 quarters · filed 2026-03-31 | $23.03K derived: sum of 3 quarters · filed 2026-08-12 | -$594.15K 10-K · filed 2026-03-31 |
| 2025-09-30 | -$214.53K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$22.25K derived: sum of 2 quarters · filed 2026-08-12 | -$639.42K 10-Q · filed 2025-11-13 | -$608.91K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $192.28K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | -$424.89K 10-Q · filed 2026-08-12 | -$394.38K derived: sum of 3 quarters · filed 2026-08-12 | -$483.68K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | -$617.18K 10-Q · filed 2026-05-14 | -$586.66K derived: sum of 2 quarters · filed 2026-05-14 | -$675.97K derived: sum of 3 quarters · filed 2026-05-14 | -$530.09K derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $30.52K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | -$58.79K derived: sum of 2 quarters · filed 2026-03-31 | $87.09K derived: sum of 3 quarters · filed 2026-03-31 | $184.78K 10-K · filed 2026-03-31 |
| 2024-09-30 | -$89.31K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $56.57K derived: sum of 2 quarters · filed 2025-11-13 | $154.27K 10-Q · filed 2025-11-13 | -$86.74K derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $145.88K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $243.58K 10-Q · filed 2025-08-14 | $2.57K derived: sum of 3 quarters · filed 2025-08-14 | $123.03K derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $97.70K 10-Q · filed 2025-05-14 | -$143.31K derived: sum of 2 quarters · filed 2025-05-14 | -$22.84K derived: sum of 3 quarters · filed 2025-05-14 | -$468.14K derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | -$241.01K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | -$120.54K derived: sum of 2 quarters · filed 2025-03-28 | -$565.84K derived: sum of 3 quarters · filed 2025-03-28 | -$389.52K 10-K · filed 2025-03-28 |
| 2023-09-30 | $120.47K derived: 10-Q 9 month − 10-Q/A 6 month · filed 2024-11-12 | -$324.83K derived: sum of 2 quarters · filed 2024-11-12 | -$148.52K 10-Q · filed 2024-11-12 | $23.86K derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | -$445.30K derived: 10-Q/A 6 month − 10-Q 3 month · filed 2024-08-16 | -$268.98K 10-Q/A · filed 2024-08-16 | -$96.60K derived: sum of 3 quarters · filed 2024-08-16 | $251.08K derived: sum of 4 quarters · filed 2024-08-16 |
| 2023-03-31 | $176.32K 10-Q · filed 2024-05-13 | $348.70K derived: sum of 2 quarters · filed 2024-05-13 | $696.38K derived: sum of 3 quarters · filed 2024-05-13 | |
| 2022-12-31 | $172.38K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | $520.07K derived: sum of 2 quarters · filed 2024-04-01 | $152.08K 10-K · filed 2024-04-01 | |
| 2022-09-30 | $347.68K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | -$20.30K 10-Q · filed 2023-11-13 | ||
| 2022-06-30 | -$367.98K 10-Q · filed 2023-09-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| Context Therapeutics Inc. (CNTX) | United States | $0.034B | -1.10 |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B |